Sitting still should not be an option – though many organisations seem to be doing just that, by cutting costs and reducing sales force or building economies of scale through merger and acquisition.

Nanobodies are smaller than conventional monoclonal antibodies and, according to their developers, can offer greater stability, higher potency, and lower production or synthesis costs. Sanofi's ...